TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05284227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Clinical Decision Support Application
Description: Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard procedures of the hospital and Sham Clinical Decision Support Application
Description: Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
Study: NCT06102070

Intervention type: OTHER
Intervention: Blood samples drawing
Description: 10 ml of periferal blood
Study: NCT06075433

Intervention type: DEVICE
Intervention: Genoss DES stent
Description: The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Study: NCT05943379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC in Combination with gemcitabine
Description: RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W
Study: NCT06102070

Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy only in some index cases depending of the pathology at the recruitment
Study: NCT04768621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionary
Description: Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionary
Description: Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
Study: NCT04957628

Intervention type: BEHAVIORAL
Intervention: Harmful alcohol use treatment
Description: Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.

Intervention type: BEHAVIORAL
Intervention: Non-prescribed psychoactive medicinal use treatment
Description: Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
Study: NCT05110300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body weight support system control group
Description: Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body weight support system with balance perturbations
Description: Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
Study: NCT05931601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Description: See arm description
Study: NCT05509426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
Study: NCT05230472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 60 mg tab
Study: NCT06344299

Intervention type: OTHER
Intervention: potential predictors
Description: Researchers want to investigate some important factors that influence elderly patients not to undergo radical surgery.
Study: NCT04807218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virta Health
Description: The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virta Health
Description: The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
Study: NCT06110208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLL1 and CD38 dual-target CAR-T injection
Description: CLL1 and CD38 dual-target CAR-T injection
Study: NCT05786508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partners4Pain program
Description: Partners4Pain is a self-management program of evidence based complementary and integrative health approaches for pain including pain education, mindfulness, cognitive behavioral approaches, and neck/back specific exercises.~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Key to Wellbeing program
Description: Keys to Wellbeing is a general health and wellbeing education program addressing topics such as keeping socially connected, finding meaning and purpose, addressing mental health, and keeping physically fit. The program was designed to control for time, attention, and many other key contextual factors (e.g., program format, materials).~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks
Study: NCT04890470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin (24 IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: intranasal administration of vasopressin (20 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration of placebo
Study: NCT05785429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
Study: NCT05878847

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q-actin
Description: idoBR1 is an iminosugar amino acid isolated from fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae), which has been shown to have anti-inflammatory activity. IminoTech Inc in the USA has produced a quality-controlled cucumber extract containing measured idoBR1 (Q-actin™) that has given good results in osteo-arthritis from oral use.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05593796

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: 12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: 12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
Study: NCT05838157

Intervention type: BIOLOGICAL
Intervention: prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)
Description: at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
Study: NCT05961891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations
Description: 1. The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~2. The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~3. The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~4. A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~5. The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~6. The finger is immobilized for two weeks in a below elbow dorsal slab.~7. Patients are followed up for 3 months. Postoperative complications and their management will be recorded.
Study: NCT06104267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients
Description: The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group.
Study: NCT05753059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendroflumethiazide
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendroflumethiazide
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Study: NCT06130722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL115
Description: FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
Study: NCT05104242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in Advanced Glycation End-Products (AGE)
Description: The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences
Study: NCT05476770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Dose will be assigned at study entry. Give IV over 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Dose will be assigned at study entry. Give IV over 15 minutes.
Study: NCT05575089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training - Powerbreath
Description: The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise in cycle ergometer
Description: 10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in cycle ergometer
Description: 10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep breathing exercises
Description: Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises
Description: Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
Study: NCT06081387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.
Study: NCT04859426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral
Study: NCT05733156

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + LDRT
Description: Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
Study: NCT05023993

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Complete home exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete home exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Given PO
Study: NCT04602117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Description: SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly.
Study: NCT04753749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)
Description: Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard DAPT
Description: Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
Study: NCT05195658

Intervention type: DEVICE
Intervention: Thrombectomy and Stenting under neuroprotection
Description: Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center.
Study: NCT05039970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WellQuest™
Description: WellQuest™ is a mobile device-based serious health game.
Study: NCT05355844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Description: Benzoyl peroxide application in the incision area before surgery

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Benzoyl peroxide
Description: Benzoyl peroxide application in the incision area before surgery
Study: NCT04866602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atoguanil
Description: Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone
Description: Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
Study: NCT04920838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide and Ciclésonide
Description: Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 20Mg Oral Tablet
Description: 20 mg tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxétine and Budésonide
Description: Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
Study: NCT06448611

Intervention type: OTHER
Intervention: Blood Test
Description: Research and quantification of Circulating Tumor Cells
Study: NCT05292716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: MitraClip
Study: NCT06143267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of either NST or placebo at different blood glucose levels
Description: In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.